School of Medicine
Showing 101-160 of 160 Results
-
Dale Gene O'Brien
Adjunct Clinical Assistant Professor, Medicine - Oncology
BioDale O’Brien, MD, MPH is adjunct faculty at the Stanford University School of Medicine in the Oncology Division. He founded several medical clinics for vulnerable populations in under-resourced areas of northern California where he has been a practicing physician for more than four decades.
A graduate of the University of Missouri School of Medicine, he took postgraduate training at the Oregon Health & Science University, and the University of California (San Francisco) / University of California School of Public Health. He is board certified by the American Board of Family Medicine and by the American Board of Preventive Medicine.
Dr. O'Brien treated hippies at the White Bird Clinic in Eugene, Oregon in the mid-70s; served as the acting Health Officer of the Shasta County Health Department in California; and spent two years in the early 80s as an affiliate of the European Branch Headquarters of the World Health Organization in Denmark.
As the Executive Director of the nonprofit Cancer Patients Alliance (CPA) since 2001, Dr. O’Brien and his team have advocated for and supported low-income Latino community members, immigrants and farm workers with cancer in the Salinas Valley agricultural region of Monterey County, California.
Dr. O’Brien was Co-Principal Investigator of the Stanford Cancer Institute's Developmental Research Award in Translational Science, "Building an Academic-Community Partnership to Understand and Address Barriers to Cancer Care in the Salinas Valley Region of Monterey County," 2010 – 2015.
CPA has trained a number of Stanford University medical and post-doctoral students on behalf of the Valley Fellowship Program beginning in 2010 until the present.
Dr. O'Brien was a member of the Stanford / Medable team that developed the cancer aftercare app called TOGETHERCare - per NIH / NCI (SBIR 363) Phase 1 and 2 grants from 9/18/2017 until 9/30/2022.
Dr. O’Brien was on the Stanford-based research team in 2018 that piloted and studied the efficacy of the “Healthkey” behavioral health app for SAMHSA, CDC and the Council of State and Territorial Epidemiologists.
Beginning 2019, he was Co-Principal Investigator with the Stanford University group that has helped reduce cancer disparities by increasing access to the emerging DNA technologies - and facilitating cultural translation in Monterey County - pursuant to 4-year support from the California Initiative to Advance Precision Medicine.
In 2021, CPA received a 5-year grant award from the Robert Wood Johnson Foundation to further their advocacy work with the Latino community and farm workers with cancer in the Salinas Valley.
In June 2021, CPA was selected by the California GOTV medical academic consortium including the Stanford University School of Medicine as led by UCLA - to conduct the "Get Out the Vaccine to Stop Covid-19" initiative for low-income populations in Monterey County, California.
Dr. O'Brien was awarded a grant from SAMHSA through the California Department of Health Care Services (administered by Sierra Health Foundation) as the Lead for the 2024-2025 collaborative consisting of CPA, Monterey County Behavioral Health, Mujeres en Acción, and NAMI Monterey County for the "Behavioral Health Recovery, Access and Equity for Latinos" (BHRAEL) initiative.
Since 2016 Dr. O'Brien has been on the Institutional Review Board of Clinica de Salud del Valle de Salinas. He is currently a member of the Stanford Cancer Institute Community Advisory Board. Dr. O’Brien is a past editor of the Berkeley Wellness Letter, Medicine on the Net and Cancer Informatics. -
Judy Yang Pagtama, MSN, RN, FNP-C
Affiliate, Medicine - Med/Oncology
BioJudy Pagtama, MSN, RN, FNP-C is a nurse practitioner in thoracic oncology at the Stanford Cancer Center. She graduated with her Family Nurse Practitioner (FNP) degree from the University of California Los Angeles School of Nursing in 2009. Her area of clinical practice is thoracic oncology, specializing in lung cancer, thymic malignancies, and mesothelioma.
-
Minggui Pan, MD, PhD
Clinical Professor, Medicine - Oncology
BioDr. Pan is a board-certified, fellowship-trained medical oncologist with the Stanford Medicine Cancer Center and a clinical professor in the Department of Medicine, Division of Oncology.
He diagnoses and treats various oncological conditions and specializes in the treatment of bone and soft tissue sarcoma. He creates personalized and comprehensive care plans for each patient he serves.
Dr. Pan’s research focuses include understanding how genomic alterations impact the biological behavior and prognosis of sarcomas. In his work, he identifies new targets for developing innovative therapeutics for sarcoma treatment.
Dr. Pan has more than eighty publications and presented many abstracts in several cancer and immunology conferences. His papers have been published in the Journal of Clinical Oncology, JCO Precision Oncology, Clinical Cancer Research, Nature Review Clinical Oncology, Nature Nanotechnology, Frontier Endocrinology, JCO Oncology Practice, Journal of Hematology and Oncology, British Journal of Cancer Reports, and other peer-reviewed journals. He has also presented to his peers at international, national, and regional meetings, including the annual meetings of American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), European Society for Medical Oncology (ESMO), Chinese Society Of Clinical Oncology (CSCO), Connective Tissue Oncology Society (CTOS) and others.
Dr. Pan is a member of American Society of Clinical Oncology, American Association for Cancer Research, American Association of Immunologists, American Association for Advancement of Science, Society for Immunotherapy of Cancer, and Connective Tissue Oncology Society. Dr. Pan is also an adjunct investigator with Kaiser Permanente Division of Research. -
Divya Parikh, MD
Clinical Assistant Professor, Medicine - Oncology
BioDr. Divya Parikh is board-certified in both medical oncology and internal medicine. She obtained her medical degree from Boston University School of Medicine and completed both her residency and fellowship through Stanford University. During her fellowship, she simultaneously earned a Master of Science in health policy from Stanford University.
Dr. Parikh specializes in the care of patients with genitourinary cancers. In addition to her clinical responsibilities, she currently is a clinical assistant professor of medical oncology at Stanford School of Medicine. She mentors medical residents and fellows by sharing her insights, knowledge, and expertise.
Dr. Parikh has a strong research background. She has published in multiple academic journals and presented her findings through poster and oral presentations at various medical conferences. -
Neha Patel, MD
Clinical Assistant Professor, Medicine - Oncology
BioDr. Neha Patel is a triple board-certified, fellowship-trained medical oncologist with Stanford Health Care. She is also a clinical assistant professor in the Department of Medicine, Division of Oncology at Stanford University School of Medicine.
Dr. Patel provides expert, personalized care for patients with both common and rare cancers and specializes in treating patients with genitourinary cancer. She is deeply committed to delivering comprehensive, patient-centered oncology services, with an emphasis on helping individuals and their families understand their diagnosis and navigate treatment options with confidence and clarity.
Her research focuses on designing and implementing system-level interventions to advance equitable, high-value cancer care. Dr. Patel is particularly passionate about integrating oncology and palliative (symptom-relieving) care—creating collaborative models that improve patient outcomes, elevate the quality of life, and enhance the overall care experience.
Known for her compassionate and relational approach, Dr. Patel builds strong, trusting partnerships with the patients and families she serves. She prioritizes care that aligns with each individual’s values, preferences, and goals, with the aim of achieving the best possible quality of life and longevity. -
Mark Pegram
Susy Yuan-Huey Hung Professor
On Partial Leave from 03/01/2025 To 11/30/2025Current Research and Scholarly InterestsMolecular mechanisms of targeted therapy resistance in breast and other cancers
-
Harlan Pinto
Associate Professor of Medicine (Oncology), Emeritus
Current Research and Scholarly InterestsClinical Interests: general oncology, head and neck cancer Research Interests: chemoprevention trials and combined modality approaches to head and neck cancer
-
Kavitha Ramchandran
Clinical Professor, Medicine - Oncology
Current Research and Scholarly InterestsMy research focuses on innovative models of care delivey to understand how to integrate primary and specialist palliative care. We also do work in palliative care education and how to scale our education to be impactful and sustainable. We are evaluating online models.
In cancer care I do research on novel therapeutics in thoracic malignancies including immunotherapy, new targeted agents, and new sequencing of approved drugs. -
Julia D. Ransohoff
Instructor, Medicine - Oncology
BioDr. Ransohoff received her B.A. from Harvard College in Human Developmental and Regenerative Biology and completed her medical training at Stanford University, where she received her M.D., completed residency in internal medicine, and fellowship training in hematology and oncology as part of the American Board of Internal Medicine Physician Scientist Training Program.
Dr. Ransohoff is a physician-scientist dedicated to improving breast cancer treatments and outcomes through developing genomic methods to profile how tumors respond to treatment. Her research focuses on molecular approaches to understand the variable clinical responses of breast cancers to treatment at the genomic level by profiling molecular residual disease. Her current work involves exploring mechanisms of chemoresistance and immune evasion and identifying novel therapeutic targets. In related work, she also studies epidemiological risk factors for breast cancer mortality with a focus on the gut microbiome, oncofertility, and racial and ethnic differences in treatment response. Dr. Ransohoff's research has been supported by the ASCO Conquer Cancer Foundation, the Terri Brodeur Breast Cancer Foundation, the Stanford Cancer Institute, ECOG-ACRIN, and the Chan Zuckerberg Initiative.
As an Instructor in the Division of Medical Oncology, Dr. Ransohoff is also a clinically active oncologist, treating patients with breast cancer. -
Fauzia Riaz, MD, MHS
Assistant Professor of Medicine (Oncology)
BioDr. Riaz is dedicated to advancing breast cancer treatment through an innovative clinical trial program that focuses on cutting-edge therapeutics and biomarkers.
Dr. Riaz is studying circulating tumor (ct)DNA-minimal residual disease (MRD) as a pivotal biomarker for early-stage breast cancer. She aims to enhance its use in surveillance and early detection while guiding personalized treatment strategies through novel clinical trials. Furthermore, she is committed to improving immunotherapy efficacy by modifying the tumor microenvironment. Her research involves developing early-phase trials that integrate novel therapeutic approaches, combining immunotherapy and radiotherapy. As a Clinical Assistant Professor at Stanford University School of Medicine, Dr. Riaz is also committed to improving the accessibility of cutting edge therapies to all patients. She is leading a collaborative effort with multiple institutions to develop databases that track patient outcomes and inform treatment practices.
Dr. Riaz’s overarching goal is to expand early-phase clinical trials and foster academic-industry partnerships to advance the field of breast oncology and improve patient care. -
Sonia Rios-Ventura
Family Health Navigator, Medicine - Med/Oncology
BioSonia Rios-Ventura is a clinical research coordinator associate for the Stanford School of Medicine, department of Cancer Genetics and Genomics. She received her B.A. in anthropology and intensive sociology from the University of California Santa Cruz.
She is also the family health navigator for the Genetic Information and Family Testing (GIFT) Study. GIFT's mission is to help families beat cancer. It aims to save lives through education and communication about cancer risk and prevention in families. When someone learns they have a genetic mutation that increases their risk for cancer, it means their family members might also be at risk. For too long, the difficult job of talking about family cancer risk has fallen to the cancer patients alone. GIFT is here to make it easier for people to share this important information and give family members an easy way to get genetic testing to learn about their personal cancer risk. GIFT is an online program developed by cancer patients, family members, and doctors that offers a new way to, 1. Share life-saving information about family cancer risk and ways to lower that risk, 2.Connect interested family members to easy, at-home genetic testing. -
Rajat Rohatgi
Professor of Biochemistry and of Medicine (Oncology)
Current Research and Scholarly Intereststhe overall goal of my laboratory is to uncover new regulatory mechanisms in signaling systems, to understand how these mechanisms are damaged in disease states, and to devise new strategies to repair their function.
-
Mohana Roy, MD
Clinical Assistant Professor, Medicine - Oncology
BioDr. Roy is a medical oncologist and a clinical assistant professor in the Stanford University School of Medicine Department of Medicine, Division of Medical Oncology. She has expertise in Lung and Thoracic cancers, but with a broad clinical interest in oncology.
Dr. Roy became an oncologist because of her passion for patient care. She is committed to being a clinician and is focused on improving the patient experience, given how the complex process of getting cancer care can be made a bit more seamless. She is the Associate Medical Director for Quality at Stanford Cancer Center from 2022.
She had led major efforts in the cancer program including starting standardized discharge follow up for patients after hospitalization, starting same day clinical care at the cancer center, and starting the Cancer Diagnostic Clinic. The Cancer Diagnostic Clinic aims to improve wait times to see an oncology team and is for patients with an unclear diagnosis of cancer but with suspected imaging concerns or atypical pathology. This clinic also includes patients who have a carcinoma of unknown primary (CUP).
Her research interests include access to clinical trials, quality improvement and improving care delivery. In that effort, she has published on work regarding patient reported outcomes (PROs), through distress screening with the Stanford Medicine Cancer Center, and in care for patient with limited English proficiency.
Dr. Roy received her medical degree from Albert Einstein College of Medicine, and then completed residency training at Beth Israel Deaconess Medical Center. She then completed fellowship training in Hematology and Oncology at Stanford, where she was chief fellow. -
Anuja Anand Sathe
Instructor, Medicine - Oncology
Current Research and Scholarly InterestsI am interested in understanding the determinants of therapeutic resistance in cancer. I investigate the composition of the tumor microenvironment and adaptive responses to therapy using single-cell and spatial approaches.
-
Lidia Schapira
Professor of Medicine (Oncology)
BioDr. Schapira is a medical oncologist with clinical expertise in the treatment of breast cancer. As the inaugural Director of Stanford's Cancer Survivorship Program, she has developed a thriving research and clinical program focused on optimizing health outcomes for people living with and beyond cancer. Dr. Schapira is interested in training future generations of physician-scientists as well as the broader community of practicing physicians through the design of innovative educational programs. Dr. Schapira's advocacy for people with cancer led to her appointment as Editor-in-Chief of the American Society of Clinical Oncology's website for the public,Cancer.Net, a position she held from 2015 until-2021. She served on the Board of Directors of the American Psychosocial Oncology Society and as Chair of the Psychosocial Interest Group of the Multinational Society for Supportive Care in Cancer. Dr. Schapira is particularily committed to reducing inequities in cancer outcomes and improve access to cancer care and cancer clinical trials. Dr. Schapira has published numerous manuscripts, lectures both nationally and internationally on issues of cancer survivorship and served as Associate Editor of the narrative section, Art of Oncology, for the Journal of Clinical Oncology from 2013 until 2023.
-
Joseph Schroers-Martin
Assistant Professor of Medicine (Oncology)
Current Research and Scholarly InterestsMedical heme/onc focused on molecular cancer diagnostics and novel biomarkers.
-
Arpeet Tarun Shah, MD
Affiliate, Medicine - Med/Oncology
BioDr. Shah practices hematology and oncology. He has fellowship training in both specialties and is board-certified in hematology, oncology, and internal medicine.
Dr. Shah is passionate about delivering patient-centered care. He aims to balance evidence-based treatments with each patient’s individual preferences. His goal is to maximize both clinical outcomes and quality of life.
He feels privileged to have the opportunity to work so closely with patients and their families. Together, they can find and pursue what is important to them throughout their cancer journey.
In addition to providing clinical care, Dr. Shah has conducted research. His research interests include molecular testing and immunotherapy outcomes in patients with non-small cell lung cancer (NSCLC).
Dr. Shah has co-authored articles on treatment for NSCLC and other topics in publications such as Clinical Lung Cancer and Journal of Oncology Practice.
He has made presentations to his peers at the American Society of Clinical Oncology–Society for the Immunotherapy of Cancer (ASCO-SITC) annual meeting and other conferences. He also has helped develop the curriculum and taught students in hematology, oncology, internal medicine, and neurobiology. In his hematology/oncology fellowship at Stanford, he was a senior teaching fellow.
Dr. Shah was also a Johnson & Johnson Global Health Scholar, serving for two months as a visiting resident scholar in Kampala, Uganda.
When not working, he enjoys reading, trying new recipes, and exploring parks with his family. -
Sumit Shah
Clinical Associate Professor, Medicine - Oncology
Clinical Associate Professor (By courtesy), UrologyBioDr. Sumit Shah specializes in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. He also serves as an investigator on numerous clinical trials, with a focus on novel immunotherapy agents. His academic interests also include digital health technologies and novel healthcare delivery services, both in the domestic and international setting. Dr. Shah graduated with distinction in biomedical engineering from Duke University, received his medical doctorate from Stanford University, and Masters in Public Health from Harvard University. He completed his internal medicine residency at the University of California, San Francisco (UCSF) where he stayed on faculty for one year before returning to Stanford for his fellowship training in medical oncology, where he now serves on the faculty.
-
Shagufta Shaheen
Clinical Assistant Professor, Medicine - Oncology
BioDr. Shaheen specializes in the gastrointestinal malignancies and she has expertise in treating neuroendocrine tumors (NETs). Following her fellowship in Hematology and Oncology, Dr Shaheen completed an advanced fellowship in Neuroendocrine tumors from Stanford University. The NET advanced fellowship is first of its kind in United State started under the leadership of Dr Pamela Kunz who is the founding Director of the Stanford Neuroendocrine Tumor Program established in 2015. After completing her advanced fellowship, Dr Shaheen joined Stanford Oncology division as Clinical Assistant Professor. Dr Shaheen is involved in further developing the neuroendocrine oncology program at Stanford which serves as a centre of excellence in the treatment of neuroendocrine tumors. Dr Shaheen is actively involved in clinical research and clinical trials. Dr Shaheen is also involved in taking care of patients admitted to the oncology service as well as resident and fellow teaching.
-
Anjali Sibley MD, MPH
Clinical Associate Professor, Medicine - Oncology
BioDr. Sibley is a Clinical Associate Professor of Medicine (Oncology) at Stanford School of Medicine. She is the Director of the Stanford Medicine Cancer Center in Emeryville and is a board-certified, fellowship-trained hematologist and medical oncologist.
Her clinical interests include treating solid tumor cancers, lung cancers, blood cancers and benign blood conditions. She is interested in cancer prevention and reducing disparities in hematologic/oncologic care among underserved populations, and successful cancer survivorship programs.
In addition to responsibilities related to patient care and overseeing the Cancer Center in Emeryville, Dr. Sibley has developed and is leading an innovative cancer survivorship clinic, including an exercise initiative. She also is passionate about advancing clinical trial enrollment for medically underserved populations and she serves on the Cancer Network’s East Bay Health Equity Committee leading lung cancer screening efforts in the East Bay. She is also working on a Stanford Cancer Institute-funded study examining psychosocial factors and cardiac health in Black cancer patients in the East Bay.
She believes that providing patient care is a true privilege. Dr. Sibley utilizes a patient-centered practice approach that addresses multiple aspects of a patient’s well-being. Her research interests have included chemoprevention of breast cancer and the development of magnetic resonance imaging technology in breast cancer detection and mapping. She has also led community-based efforts to implement low-dose computed tomography (LDCT) as a screening tool for cancer.
Dr. Sibley’s publications include articles on breast cancer prevention, breast magnetic resonance imaging, and other topics. Her work has appeared in American Journal of Hematology, JAMA, the Breast Journal, Internal Medicine News, and elsewhere. Dr. Sibley was invited to deliver a peer-reviewed presentation on community-based cancer screening and preventive education to the Global Health Council. Dr. Sibley is on the board of directors of the Cancer Support Community SF Bay Area. She has also served as a clinic physician for the Native American Health Center of Oakland, on the Committee on Health Equity of the American Public Health Association, and as chair and vice chair of the Cancer Forum Caucus of the American Public Health Association. She is a member of the American Society of Clinical Oncology, American Society of Preventive Oncology, and American Society of Hematology. She has provided volunteer services to the Global Health Council and to the Cancer Patients Aid Association, for whom she conducted a patient screening and education program in Mumbai, India. -
Branimir I. Sikic, M. D.
Professor of Medicine (Oncology), Emeritus
Current Research and Scholarly InterestsResearch Interests: cancer pharmacology, mechanisms of resistance to anticancer drugs, regulation and function of MDR1 and tubulin genes, CD47 as a target for activation of anticancer macrophases, Phase I trials of new drugs, gene expression profiling of cancers
-
Allyson Spence
Clinical Assistant Professor, Medicine - Oncology
BioAllyson Spence MD, PhD is a Clinical Assistant Professor of Medicine in the Stanford University School of Medicine. She received her MD, PhD in the MSTP program at Vanderbilt University School of Medicine, studying basic mechanisms of transcription using Saccharomyces cerevisiae as a model system in the laboratory of Dr. Tony Weil. She went on to an internship and residency at the University of Pennsylvania before returning to Stanford to complete her Oncology fellowship training. She did a postdoctoral fellowship at Stanford in the department of Molecular Biology under the auspices of Dr. Margaret Fuller, where she was the recipient of a career award.
She has transitioned from basic science research to clinical medicine where she sees patients diagnosed with breast cancer. Additionally, she has an appointment at the Palo Alto VA as a staff oncologist where she focuses on women's cancers and women at high risk of developing breast and gynecologic cancers. She is involved in several translational research projects at the VA, as well as being involved in clinical trials. -
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Current Research and Scholarly InterestsClinical interests: general oncology, genito-urinary malignancy Research interests: conducting clinical trials in advanced prostate cancer, bladder cancer and renal cell carcinoma
-
Frank E. Stockdale
Maureen Lyles D'Ambrogio Professor in the School of Medicine, Emeritus
Current Research and Scholarly InterestsLaboratory and clinical research in breast cancer ; Normal and abornal differentiation and growth
-
Takeshi Sugio
Postdoctoral Scholar, Oncology
BioI am a physician-scientist and hematologist focused on clinical translation of T-cell biology. I received my MD from Kyushu University, and subsequently completed Residency Training at Toranomon Hospital, the largest transplant center in Japan. I continued my Hematology training at Kyushu University, where I qualified as a Board-certified specialist (2017) and supervisory hematologist (2021) by the Japanese Society of Hematology. For my PhD (2014-19), I studied expression profiles and histologic features of TCLs. I discovered distinct TCL clinical groups identified by infiltrating immune cell patterns in the microenvironment. Based on my dissertation work (Sugio, et al 2018 Blood Advances), I planned and conducted a Phase II trial of PD1 inhibition for relapsed/refractory TCL (UMIN000034499). I joined the Alizadeh lab at Stanford in 2021, where I am developing tools to analyze immune status using liquid biopsies.
-
Fangdi Sun
Clinical Instructor, Medicine - Oncology
BioDr. Sun is a medical oncologist and clinical investigator at Stanford University. She specializes in the treatment of patients with head and neck malignancies, with specific interests in virus-driven malignancies and novel, biomarker-guided therapies in head and neck cancer. She received her medical degree from Harvard Medical School, followed by a residency and chief residency at the University of California, San Francisco, and then served as chief fellow in hematology and medical oncology at Stanford University. She has earned honors and recognition from the American Association of Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and International Association for the Study of Lung Cancer (IASLC), among other organizations.
-
Melinda L. Telli, M.D.
Professor of Medicine (Oncology)
Current Research and Scholarly InterestsMy research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Other areas of interest include prevention of cardiac damage associated with breast cancer treatment and cardiotoxicity of anti-cancer agents.
-
Haluk Tezcan, MD
Adjunct Clinical Associate Professor, Medicine - Oncology
BioClinical focus:
Breast Oncology
Molecular Diagnostics
Dr. Tezcan is a medical oncologist and hematologist with over three decades of diverse experience in cancer management and research.
He is leading the clinical development of Droplet Biosciences' novel liquid biopsy technology, a first-in-class lymphatic fluid molecular residual disease assessment, overseeing the scientific and clinical development of the technology. With over three decades of direct patient care and clinical trial experience as a principal investigator and director, both in academia and private practice, he has a firsthand understanding of the unmet clinical needs of physicians and patients, as well as broad experience in clinical trial design and implementation.
He is also co-principal at Athea Oncology, guiding practices and hospitals in developing clinical trial programs and high-value real-world data collection and diagnostic companies in clinical development. He is also a reviewer of JCO Precision Medicine.
Before joining Athea Oncology and Droplet Biosciences, he was the co-founder of LexentBio, which was successfully acquired by Roche/FMI. He also served as Director of Translational Medicine at Genomic Health and as Vice President, leading oncology development at Counsyl, where he integrated science with clinical product development. He established the CA.RE.foundation, a cancer research foundation dedicated to enabling the execution of clinical trials across community oncology sites throughout the Northwest US. He has independently built multiple software tools to help oncologists navigate the practical realities of their daily work. -
Heather Wakelee
Winston Chen and Phyllis Huang Professor
Current Research and Scholarly InterestsDr. Wakelee's research is focused on clinical trials and translational efforts in patients with lung cancer and other thoracic malignancies such as thymoma and thymic carcinoma. Other interests include translation projects in thoracic malignancies and collaborations with population scientists regarding lung cancer questions.
-
Maggie Zhou
Instructor, Medicine - Oncology
BioDr. Zhou is an Instructor in the Division of Oncology at Stanford University with an academic focus in sarcoma. She graduated from Yale University with a B.A. and double majored in economics and molecular, cellular, and developmental biology. She subsequently received her M.D. from Stanford University School of Medicine, where she completed her internal medicine residency and fellowship training.
Her research interests center around the development of novel therapeutics, understanding pathophysiology of rare sarcoma subtypes, and evaluating the utility of circulating tumor DNA for assessing disease response and detecting minimal residual disease. She has co-authored over 20 peer-reviewed publications, including in Clinical Cancer Research and Nature Cell, and is an active member of the Sarcoma Clinical Trial Working Group in the Hoosier Cancer Research Network. Her research has been supported by the Chinese American Hematologist and Oncologist Network and Sarcoma Alliance for Research through Collaboration.
